Crenigacestat (LY3039478)

Catalog No.S7169 Batch:S716901

Print

Technical Data

Formula

C22H23F3N4O4
Molecular Weight 464.44 CAS No. 1421438-81-4
Solubility (25°C)* In vitro DMSO 92 mg/mL (198.08 mM)
Ethanol 92 mg/mL (198.08 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Crenigacestat (LY3039478) is an oral Notch and gamma-secretase inhibitor with IC50 of 0.41 nM for Notch.
Targets
Notch [1]
~1 nM
In vitro LY3039478 is a novel small molecule that is an exquisitely potent inhibitor of Notch-1 intracellular domain (N1ICD) cleavage with an IC50 of ∼1nM in most of the tumor cell lines tested. LY3039478 also potently inhibits mutant Notch receptor activity[2]. Treatment with a gamma secretase inhibitor, LY3039478, significantly inhibited the growth of 2 CCRCC(Clear cell renal cell carcinoma) cell lines in a concentration dependent manner. LY3039478 treatment also led to decreased expression of Myc and Cyclin A1, two genes that were part of the NOTCH driven proliferative signature in murine and human model systems. LY3039478 treatment also led to G0/G1 cell cycle arrest in CCRCC cells[3].
In vivo In mice, its oral bioavalability(%F) is 65%, clearance(CL)=41 mL/min/kg, VDss = 3.8 L/kg. In Rats, its oral bioavalability(%F) is 65%, CL=98 mL/min/kg, VDss=4.9 L/kg. In Dogs, its oral bioavalability (%F) is 67%, CL=3.8 mL/min/kg, VDss=1.4 L/kg[1]. In a xenograft tumor model, LY3039478 inhibited N1ICD cleavage and expression of Notch-regulated genes in the tumor microenvironment. The inhibition of Notch cleavage also resulted in the induction of apoptosis in a Notch-dependent xenograft model[2]. In immunodeficient NSG mice xenografted with 769-P CCRCC cells, LY3039478 treatment resulted in significantly increased survival and delayed tumor growth in independent cohorts of mice demonstrating in vivo efficacy in CCRCC[3].

Protocol (from reference)

Cell Assay:

[4]
  • Cell lines

    K07074 cells

  • Concentrations

    100 nM

  • Incubation Time

    24, 48, 72, 96 h

  • Method

    K07074 cells were plated to 24-well plates at 105 cell/well. Viability of cells was assessed in quadruplicates at indicated timepoints using the CellTiter-Glo luminescent cell viability assay. To study the effect of the small molecular compounds on K07074 cell growth the compounds or DMSO were added to the growth media 24 h after seeding. The cells were incubated with inhibitors and DMSO as indicated. Cell viability was assessed as described above. Each experiment was carried out in triplicate and at least 3 independent experiments were performed.
Animal Study:

[3]
  • Animal Models

    Mice

  • Dosages

    8 mg/kg

  • Administration

    oral gavage

Customer Product Validation

Data from [Data independently produced by , , Eur Rev Med Pharmacol Sci, 2018, 22(13):4121-4127]

Selleck's Crenigacestat (LY3039478) has been cited by 25 publications

Tolerable glycometabolic stress boosts cancer cell resilience through altered N-glycosylation and Notch signaling activation [ Cell Death Dis, 2024, 15(1):53] PubMed: 38225221
Cellular senescence primes liver fibrosis regression through Notch-EZH2 [ MedComm (2020), 2023, 4(5):e346] PubMed: 37614965
Cellular senescence primes liver fibrosis regression through Notch-EZH2 [ MedComm -2020), 2023, 4(5):e346] PubMed: 37614965
Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells [ Blood Adv, 2023, 7(14):3551-3560] PubMed: 37042949
Familial Alzheimer's disease-associated PSEN1 mutations affect neurodevelopment through increased Notch signaling [ Stem Cell Reports, 2023, 18(7):1516-1533] PubMed: 37352850
Notch signaling regulates immunosuppressive tumor-associated macrophage function in pancreatic cancer [ bioRxiv, 2023, 2023.01.11.523584] PubMed: 36711890
Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through eNOS [ Hepatology, 2022, 10.1002/hep.32332] PubMed: 35006626
CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype [ J Exp Clin Cancer Res, 2022, 41(1):65] PubMed: 35172861
Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition [ J Exp Clin Cancer Res, 2022, 41(1):331] PubMed: 36443822
Establishment and characterization of immortalized sweat gland myoepithelial cells [ Sci Rep, 2022, 12(1):7] PubMed: 34997030

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.